# A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

> **NCT05814848** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Changhai Hospital** · enrollment: 13 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Lymphoma

## Interventions

- **DRUG:** Relmacabtagene Autoleucel Injection

## Key facts

- **NCT ID:** NCT05814848
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-06-20
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814848, "A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05814848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*